The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Aromasil     (8R,9S,10S,13S,14S)-10,13- dimethyl-6...

Synonyms: Aromasin, Nikidess, Aromasine, EXEMESTANE, Exemestano, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of D00963


High impact information on D00963


Chemical compound and disease context of D00963


Biological context of D00963


Anatomical context of D00963


Associations of D00963 with other chemical compounds


Gene context of D00963


Analytical, diagnostic and therapeutic context of D00963


  1. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. Lønning, P.E., Geisler, J., Krag, L.E., Erikstein, B., Bremnes, Y., Hagen, A.I., Schlichting, E., Lien, E.A., Ofjord, E.S., Paolini, J., Polli, A., Massimini, G. J. Clin. Oncol. (2005) [Pubmed]
  2. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group. Jones, S., Vogel, C., Arkhipov, A., Fehrenbacher, L., Eisenberg, P., Cooper, B., Honig, S., Polli, A., Whaley, F., di Salle, E., Tiffany, J., Consonni, A., Miller, L. J. Clin. Oncol. (1999) [Pubmed]
  3. Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma. Cleton-Jansen, A.M., van Beerendonk, H.M., Baelde, H.J., Bovée, J.V., Karperien, M., Hogendoorn, P.C. Clin. Cancer Res. (2005) [Pubmed]
  4. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Vonderheide, R.H., LoRusso, P.M., Khalil, M., Gartner, E.M., Khaira, D., Soulieres, D., Dorazio, P., Trosko, J.A., Rüter, J., Mariani, G.L., Usari, T., Domchek, S.M. Clin. Cancer Res. (2010) [Pubmed]
  5. Aromatase inhibitors in the treatment and prevention of breast cancer. Goss, P.E., Strasser, K. J. Clin. Oncol. (2001) [Pubmed]
  6. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. Lønning, P.E., Bajetta, E., Murray, R., Tubiana-Hulin, M., Eisenberg, P.D., Mickiewicz, E., Celio, L., Pitt, P., Mita, M., Aaronson, N.K., Fowst, C., Arkhipov, A., di Salle, E., Polli, A., Massimini, G. J. Clin. Oncol. (2000) [Pubmed]
  7. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Evans, T.R., Di Salle, E., Ornati, G., Lassus, M., Benedetti, M.S., Pianezzola, E., Coombes, R.C. Cancer Res. (1992) [Pubmed]
  8. Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer. Love, R.R., Hutson, P.R., Havighurst, T.C., Cleary, J.F. Clin. Cancer Res. (2005) [Pubmed]
  9. Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients. Anker, G.B., Refsum, H., Ueland, P.M., Johannessen, D.C., Lien, E.A., Lonning, P.E. Clin. Chem. (1999) [Pubmed]
  10. Cardiovascular safety profiles of aromatase inhibitors : a comparative review. Nabholtz, J.M., Gligorov, J. Drug safety : an international journal of medical toxicology and drug experience. (2006) [Pubmed]
  11. Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase. Hong, Y., Yu, B., Sherman, M., Yuan, Y.C., Zhou, D., Chen, S. Mol. Endocrinol. (2007) [Pubmed]
  12. Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males. Mauras, N., Lima, J., Patel, D., Rini, A., di Salle, E., Kwok, A., Lippe, B. J. Clin. Endocrinol. Metab. (2003) [Pubmed]
  13. Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer. Hutson, P.R., Love, R.R., Havighurst, T.C., Rogers, E., Cleary, J.F. Clin. Cancer Res. (2005) [Pubmed]
  14. Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. Francini, G., Petrioli, R., Montagnani, A., Cadirni, A., Campagna, S., Francini, E., Gonnelli, S. Br. J. Cancer (2006) [Pubmed]
  15. Reducing breast cancer incidence in familial breast cancer: overlooking the present panorama. Marchetti, P., Di Rocco, C.Z., Ricevuto, E., Bisegna, R., Cianci, G., Calista, F., Sidoni, T., Porzio, G., Ficorella, C. Ann. Oncol. (2004) [Pubmed]
  16. 5alpha-Reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production. Suzuki, T., Miki, Y., Moriya, T., Akahira, J., Ishida, T., Hirakawa, H., Yamaguchi, Y., Hayashi, S., Sasano, H. Int. J. Cancer (2007) [Pubmed]
  17. Comparison of the effects of the irreversible aromatase inhibitor exemestane with atamestane and MDL 18962 in rats with DMBA-induced mammary tumours. Zaccheo, T., Giudici, D., Ornati, G., Panzeri, A., di Salle, E. Eur. J. Cancer (1991) [Pubmed]
  18. What do we know about the mechanisms of aromatase inhibitor resistance? Chen, S., Masri, S., Wang, X., Phung, S., Yuan, Y.C., Wu, X. J. Steroid Biochem. Mol. Biol. (2006) [Pubmed]
  19. Effects of a combination of exemestane and paclitaxel on human tumor cells in vitro. Chen, D., Hackl, W., Ortmann, O., Treeck, O. Anticancer Drugs (2004) [Pubmed]
  20. Aromatase inhibition: translation into a successful therapeutic approach. Geisler, J., Lønning, P.E. Clin. Cancer Res. (2005) [Pubmed]
  21. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data. Buzdar, A.U., Cuzick, J. Clin. Cancer Res. (2006) [Pubmed]
  22. Aromatase inhibitors in breast cancer. Brodie, A. Trends Endocrinol. Metab. (2002) [Pubmed]
  23. Prevention strategies with aromatase inhibitors. Goss, P.E., Strasser-Weippl, K. Clin. Cancer Res. (2004) [Pubmed]
  24. A human and mouse pregnane X receptor reporter gene assay in combination with cytotoxicity measurements as a tool to evaluate species-specific CYP3A induction. Vignati, L.A., Bogni, A., Grossi, P., Monshouwer, M. Toxicology (2004) [Pubmed]
  25. Changes in vascular endothelial growth factor (VEGF) after chemoendocrine therapy in breast cancer. Fersis, N., Smyczek-Gargya, B., Armeanu, S., Gagulic, E., Pantic, L., Relakis, K., Friedrich, M., Wallwiener, D. Eur. J. Gynaecol. Oncol. (2004) [Pubmed]
  26. A feasibility study of the efficacy and tolerability of the combination of Exemestane with the COX-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancer. Canney, P.A., Machin, M.A., Curto, J. Eur. J. Cancer (2006) [Pubmed]
  27. Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors. Boeddinghaus, I.M., Dowsett, M. J. Steroid Biochem. Mol. Biol. (2001) [Pubmed]
  28. Effects of exemestane and tamoxifen in a postmenopausal breast cancer model. Jelovac, D., Macedo, L., Handratta, V., Long, B.J., Goloubeva, O.G., Ingle, J.N., Brodie, A.M. Clin. Cancer Res. (2004) [Pubmed]
  29. Exemestane: a review of its use in postmenopausal women with advanced breast cancer. Clemett, D., Lamb, H.M. Drugs (2000) [Pubmed]
WikiGenes - Universities